Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
34 hedge funds and large institutions have $70.6M invested in Fusion Pharmaceuticals Inc. Common Shares in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 5 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
15% more capital invested
Capital invested by funds: $61.3M → $70.6M (+$9.27M)
10% more funds holding
Funds holding: 31 → 34 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$1.65M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$146K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$125K |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$97.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$85.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$2.62M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.02M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$509K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$327K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$46.9K |
FUSN Hedge Fund Activity: Q3 2022 in Review
34 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q3 2022, worth a combined $70.6M — up 15% from $61.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new FUSN positions and 5 closed out — a net gain of 3 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $1.65M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $2.62M sold.
- 34 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q3 2022, up from 31 in Q2 2022.
- Funds reported $70.6M of Fusion Pharmaceuticals Inc. Common Shares stock for Q3 2022, up 15% quarter-over-quarter.
- 8 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q3 2022 and 5 closed out, a net change of +3 holders.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q3 2022 was RA Capital Management, an estimated $1.65M added.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q3 2022 was Perceptive Advisors, an estimated $2.62M sold.
Based on aggregated 13F filings for Q3 2022.